Web17 set 2024 · Imfinzi is a medicine used to treat lung cancer. It for use in adults with: non-small cell lung cancer (NSCLC) that cannot be removed by surgery but is not getting … European Medicines Agency - Date Content ; 13/04/2024: Opinion/decision on a … The European Medicines Agency (EMA) is responsible for the scientific evaluation … Careers - Imfinzi European Medicines Agency Citizens of the EU and natural or legal persons residing or having their … EMA's post-authorisation procedural advice document provides a printable overview … Product information, including the package leaflets for patients; Major reviews of … The Management Board consists of 36 members, appointed to act in the public … Glossaries - Imfinzi European Medicines Agency Web24 set 2024 · IMFINZI è indicato in monoterapia per il trattamento del carcinoma polmonare non a piccole cellule (NSCLC) localmente avanzato, non resecabile, negli adulti il cui tumore presenta un’espressione di PD-L1 ≥ 1% sulle cellule tumorali e la cui malattia non è progredita a seguito di chemioradioterapia a base di platino (vedere paragrafo 5.1).
Imfinzi 50 mg/mL concentrate for solution for infusion
WebIMFINZI, in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). IMFINZI in combination with IMJUDO is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). Immune-Mediated Pneumonitis Web24 ott 2024 · Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering … log a user out with powershell
AUSTRALIAN PRODUCT INFORMATION IMFINZI (durvalumab) …
WebOn May 1, 2024, the U.S. Food and Drug Administration granted accelerated approval to durvalumab (IMFINZI, AstraZeneca UK Limited) for the treatment of patients with locally … Web5 set 2024 · 1. Imfinzi [package insert]. Wilmington, DE; AstraZeneca Pharmaceuticals LP; February 2024. Accessed July 2024. 2. Massard C, Gordon MS, Sharma S, et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. WebImfinzi Package Insert Guideline Imfinzi is considered medically necessary for members ≥ 18 years of age, for use as a single agent, when prescribed by an oncologist for the following indications: A. Urothelial Carcinoma (MCC); either:* a. Disease must have progressed during or following platinum-containing chemotherapy b. inductive braking